ASP0113 + Placebo

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Cytomegalovirus (CMV)-Positive Recipients

Conditions

Cytomegalovirus (CMV)-Positive Recipients, Allogeneic, Hematopoietic Cell Transplant (HCT)

Trial Timeline

Sep 11, 2013 → Mar 1, 2022

NCT ID

NCT01877655

About ASP0113 + Placebo

ASP0113 + Placebo is a phase 3 stage product being developed by Astellas Pharma for Cytomegalovirus (CMV)-Positive Recipients. The current trial status is completed. This product is registered under clinical trial identifier NCT01877655. Target conditions include Cytomegalovirus (CMV)-Positive Recipients, Allogeneic, Hematopoietic Cell Transplant (HCT).

What happened to similar drugs?

7 of 20 similar drugs in Cytomegalovirus (CMV)-Positive Recipients were approved

Approved (7) Terminated (3) Active (10)

❌mRNA-1647ModernaPhase 3

🔄Letermovir tablet + Letermovir IVMerckPhase 3

✅LetermovirMerckApproved

🔄Letermovir + PlaceboMerckPhase 3

🔄LetermovirMerckPhase 3

🔄Valganciclovir + GanciclovirRochePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02103426	Phase 1	Completed	Dec 30, 2013	May 10, 2016	Dialysis
NCT01974206	Phase 2	Completed	Nov 20, 2013	Nov 5, 2020	Kidney Transplantation Cytomegalovirus (CMV) Negative Recipients
NCT01877655	Phase 3	Completed	Sep 11, 2013	Mar 1, 2022	Cytomegalovirus (CMV)-Positive Recipients

Competing Products

20 competing products in Cytomegalovirus (CMV)-Positive Recipients

See all competitors

Product	Company	Stage	Hype Score
mRNA-1273	Moderna	Phase 1	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 1	0
mRNA-1647	Moderna	Phase 2	0
mRNA-1647	Moderna	Phase 1	0
mRNA-1647	Moderna	Phase 3	0
ASP0113 + Placebo	Astellas Pharma	Phase 2	35
Letermovir oral granules + Letermovir tablet + Letermovir intravenous	Merck	Phase 2	35
Letermovir 240 mg Oral Tablet	Merck	Phase 2	42
Letermovir tablet + Letermovir IV	Merck	Phase 3	40
Letermovir	Merck	Phase 1	36
Letermovir	Merck	Approved	43
Letermovir 480 MG [Prevymis]	Merck	Phase 2	42
V160 Low Dose IM + V160 Medium Dose IM + V160 High Dose IM + V160 Medium Dose plus Merck Aluminum Phosphate Adjuvant (MAPA) 225 µg /dose IM + V160 High Dose plus MAPA 225 µg /dose IM + V160 Maximum Dose IM + V160 Medium Dose ID	Merck	Phase 1	29
Ganciclovir	Merck	Pre-clinical	26
Letermovir + Placebo	Merck	Phase 3	40
Letermovir	Merck	Phase 2	35